annb0t
Top 20
The positive decision from the Canadian Agency for Drugs and Technologies in Health (CADTH) recognizes the importance of this one-time, single dose innovative treatment for adults with hemophilia B who require routine prophylaxis
OTTAWA, ON, July 16, 2024 /CNW/ -- CSL Behring Canada Inc., a business unit of global biotechnology leader CSL, today announced that the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) recommended public drug plan reim...
>>> Read more: CSL Behring Announces Positive Reimbursement Decision in Canada for HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B
OTTAWA, ON, July 16, 2024 /CNW/ -- CSL Behring Canada Inc., a business unit of global biotechnology leader CSL, today announced that the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) recommended public drug plan reim...
>>> Read more: CSL Behring Announces Positive Reimbursement Decision in Canada for HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B
